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Abstract: The purpose of this study is to explain the rationale for the value of information
approach to priority setting for research and to describe the methods intuitively for those
familiar with basic decision analytical modeling. A policy-relevant case study is used to
show the feasibility of the method and to illustrate the type of output that is generated and
how these might be used to frame research recommendations. The case study relates to
the use of glycoprotein IIb/IIIa antagonists for the treatment of patients with non-ST
elevation acute coronary syndrome. This is an area that recently has been appraised by
the National Institute for Health and Clinical Excellence.
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In most developed healthcare systems, the public sector de-
votes significant resources both to healthcare services and to
health services research. Within the United Kingdom for ex-
ample, in 2000, expenditure on the National Health Service
(NHS) was £69.2 billion, 81% of which was public money
(31). In the United States, public expenditure on Medicare
and Medicaid amounted to $259.1 billion in 2002 (6). Public
funds are also spent on research and development as opposed
to health care per se. For example, in 2000, the UK Depart-
ment of Health spent £500 million on research (22). In the
United States, $18.8 billion was spent on research by the
federal government (42).
Given that an important objective for any healthcare
system is to maximize some measure of health gain from
available resources, the benefits generated by all resources,
including those that are earmarked for research, have to be
maximized. The objective of achieving efficiency in health-
related research, as well as the provision of services, will need
to address issues such as: Which clinical areas should receive
research resources? Which type of research should be under-
taken (e.g., randomized trials or observational studies)? What
end points should be measured? What are the appropriate
sample sizes for studies? This question of allocation between
provision of services and research and development clearly
is relevant from a public sector or healthcare system perspec-
tive, but it is also important if a broader societal view is taken
that would include the costs and benefits to all sectors of the
economy in providing health care and conducting research.
379
Philips et al.
Methods to establish the value for money of alterna-
tive health care technologies are well established. Cost-
effectiveness analysis is the most widely used form of eval-
uation (37). The expected additional cost of one technology
over another is compared with expected additional health
outcomes, typically expressed in terms of quality-adjusted
life years (QALYs) (i.e., the incremental cost-effectiveness
ratio [ICER]) (28). If the resultant ratio falls below a pre-
specified threshold value (which may be an administrative
“ceiling ratio,” an empirically based measure of society’s
maximum willingness to pay for additional health gains or
an explicit shadow price of a budget constraint [46]), then
the technology can be regarded as cost-effective, contingent
on the information currently available.
Analysis such as this feeds into the decision-making
process regarding which healthcare activities should be pro-
vided by the healthcare system. For example, in the United
Kingdom, the National Institute for Health and Clinical Ex-
cellence (NICE) carries out technology appraisals of specific
healthcare interventions, medicines, devices, and procedures
to establish their clinical and cost-effectiveness. On the basis
of these appraisals, NICE issues guidance to the NHS on the
most appropriate use of resources within a defined scope (i.e.,
disease area, group of patients, etc.). Similar agencies exist
to make technology coverage decisions in other jurisdictions
(25).
The appropriate methods to inform the allocation of re-
sources for research are less clear. Several methods have been
proposed and some have been used successfully to identify
priority areas for research. These methods include measures
of the burden of disease or the technology (30;45), measures
of the expected “payback” from research (5;15;35), and esti-
mates of the welfare losses due to variations in clinical prac-
tice (39). However, each of these approaches has method-
ological problems. First, they view research as a means of
changing clinical practice and not as a means of providing
additional information to reduce the uncertainty about what
is appropriate clinical practice. Indeed, measures of “pay-
back” or welfare losses due to variations in clinical prac-
tice require the analysis to identify “appropriate utilization”
or which technology should be adopted a priori. Therefore,
these methods implicitly assume that there is no uncertainty
surrounding the decision that the proposed research is sup-
posed to inform. Second, these approaches, particularly mea-
sures of disease burden, attempt to identify research priorities
using aggregate measures across broad clinical areas. How-
ever, the information generated by evaluative research is only
valuable if it informs specific clinical decisions for specific
groups of patients. The value of research in a clinical area
is simply made up of the value of research about each of
the constituent clinical decision problems faced within that
area. Therefore, if aggregate measures such as burden of dis-
ease suggest a clinical area is a “high” priority, it does not
necessarily mean that specific evaluative research relating to
any one clinical decision problem will be valuable. Similarly,
proposed research to inform a particular decision in a “low”
priority disease area may be very valuable. For this reason,
attempts to identify research priorities across broach clinical
areas using aggregate indicators may be erroneous.
To inform research priority setting, a measure of the
societal value of resolving a particular research question is
required. This finding can inform specific clinical decisions
for defined groups of patients. An appropriate methodolog-
ical framework should consider the uncertainty surrounding
the adoption of a health technology in terms of the likelihood
of making a wrong decision. It should also view the value
of research as the extent to which further information will
reduce that decision uncertainty. Given that funding for re-
search and healthcare provision ultimately comes from the
same budget, the opportunity cost of spending on research
can be seen in terms of forgone funding for health care per
se. This means that decisions regarding research must be ad-
dressed in a manner that is consistent with the way in which
decisions are made regarding healthcare provision. An ap-
propriate framework, therefore, should value the additional
information generated by research in a way that is consistent
with the objectives and the resource constraints of healthcare
provision.
Value of information (VOI) analysis offers a method-
ological framework that explicitly considers the uncertainty
surrounding the decision by a healthcare system to adopt
a health technology (11). This framework values the addi-
tional information, which may be generated by further re-
search, in a way that is consistent with the objectives and
the resource constraints of heathcare provision (the cost-
effectiveness threshold). This consistency allows a compar-
ison of the potential benefits of further research with the
costs of further investigation. If the costs of investigation
exceed the benefits, then the proposed research will not be
cost-effective.
Within this study, we present a practical application of
VOI analysis and show how it offers a powerful tool to guide
research decisions within a given area. We apply the method-
ology to a specific decision problem: the use of glycopro-
tein IIb/IIIa antagonists (GPAs) for the treatment of patients
with non-ST elevation acute coronary syndrome (ACS). This
treatment is an area that twice has been appraised by NICE
(21;29;40), who have accordingly offered specific guidance
to the UK NHS and have made recommendations for further
research (33).
VALUE OF INFORMATION ANALYSIS
VOI analysis is founded in statistical decision theory
(36;38;39) and has been successfully used in other areas of
research such as engineering and environmental risk analysis
(24;26;44). Although its use in health care has been set out
formally by several researchers (for example, see references
1;7;8;10;11;17;20), currently, there are few practical appli-
cations of the technique. In a recent comprehensive review
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of the use of the VOI technique in health risk management,
Yakota and Thompson (47) identified a total of forty-four ap-
plications, eighteen of which were within the field of medical
care.
The decision to adopt a technology based on current ev-
idence is conceptually separate from the decision to acquire
more information by conducting further research. The adop-
tion decision can be made using methods analogous to those
described above and by converting incremental ratios into net
benefits (NB) (10,43). This is done by valuing health gains in
money terms using the threshold for cost-effectiveness. The
technology offering the highest expected net benefit on the
basis of information currently available offers the best value
for money and should be regarded as cost-effective (20).
The decision to acquire more information should be
based on the consequences of the uncertainty surrounding
a decision to adopt a technology given current information.
It is inevitable that the information used to calculate costs,
outcomes, and net benefits associated with alternative health-
care technologies will be subject to uncertainty. There will
be a chance that a decision based on current information will
be “wrong,” and there will be opportunity costs in the form of
resources and health gains forgone. These expected costs of
uncertainty can be reduced by acquiring further information
through research. It is this reduction in the cost of uncertainty
that is the value of information.
Probabilistic sensitivity analysis can be undertaken to es-
tablish the uncertainty associated with the decision to adopt
a technology. This requires assigning a distribution to each
parameter within the model to reflect the uncertainty associ-
ated with its mean value and using Monte Carlo simulation to
propagate this uncertainty through the model. This approach
provides a large number of simulations of cost, effect, and
net benefit for each technology under evaluation (3).
The expected value of perfect information (EVPI) can
be calculated directly from the simulation output. The op-
portunity loss is the difference between the NB of the tech-
nology chosen to be cost-effective on the basis of expected
net benefit across all iterations and the NB of the tech-
nology that offers maximum net benefit for that particular
iteration or realization of uncertainty. Averaging these op-
portunity losses across all iterations gives the expected cost
associated with existing decision uncertainty. This cost is
the maximum payoff for a single patient from any amount
of information and, therefore, provides an estimate of the
EVPI (formal notation of the EVPI calculations can be found
at http://www.york.ac.uk/inst/che/pdf/priority.pdf and refer-
ences 1;12).
However, information is a public good (i.e., if it is avail-
able to inform the management of one patient, it is available
for that purpose in all patients). By multiplying the individual
EVPI by the expected population of patients who will bene-
fit from the information, the maximum value of information
derived from future research can be quantified. This requires
an estimate of the period of time over which the information
would be beneficial, the number of patients affected within
this period, and discounting to present values (10).
The EVPI provides a maximum value against which the
costs of research may be compared. If the costs of the pro-
posed research exceed the EVPI, the proposed research can-
not be regarded as cost-effective. Moreover, the EVPI associ-
ated with particular parameters or groups of parameters such
as utility estimates, treatment effects or costs, can also be
calculated. This EVPI for parameters (EVPPI) (1) provides
some indication of the type of future research that would
be most beneficial and could be considered cost-effective.
For example, if the EVPI for parameters subject to selection
bias such as relative treatment effect is high, a randomized
controlled trial may be required. However, if EVPI is as-
sociated with other parameters relevant to natural history,
costs or quality of life, then other research designs may be
more appropriate. The methods for calculating EVPPI are
analogous to calculating EVPI (formal notation is provided
at http://www.york.ac.uk/inst/che/pdf/priority.pdf and refer-
ences 1;12).
THE CASE STUDY
The Disease and Interventions
The case study relates to the use of GPAs, which are a class
of drug used to prevent platelet aggregation in the acute
treatment of patients with non-ST elevation ACS. The aim
of these drugs is to reduce the risk of cardiac death and
acute myocardial infarction (MI). Within the UK, two broad
groups are licensed: abciximab (ReoPro, Eli Lilly) is a mono-
clonal antibody targeted at the receptor; whereas eptifibatide
(Integrilin, Schering Plough) and tirofiban (Aggrastat, MSD)
are more conventional pharmacological receptor antagonists.
GPAs are used in two ways to manage ACS patients: either
as an adjunct to percutaneous coronary interventions (PCI;
e.g., angioplasty) or as part of medical management regard-
less of whether they go onto to have a PCI. Abciximab is
licensed currently as an adjunct to PCI, whereas tirofiban
and eptifibatide are licensed for use only in medical man-
agement. Further details of the disease can be found at
http://www.york.ac.uk/inst/che/pdf/priority.pdf.
The Model
Full details of the model has been published elsewhere
(34,41) and summary details of the model structure
and input parameters are provided at http://www.york.ac.
uk/inst/che/pdf/priority.pdf. A decision-analytic model was
developed to synthesize the available evidence regarding the
effectiveness and costs of GPAs in comparison with usual
care. The purpose of the model was to assess the cost-
effectiveness of the use of these drugs in the UK in pa-
tients with non-ST elevation ACS and to establish the value
of further research in this area. A lifetime perspective was
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adopted, benefits were measured in terms of QALYs, and
costing was carried out from the perspective of the NHS.
Three GPA-based strategies in comparison with usual care
were evaluated to represent the full range of possible ap-
proaches to using GPAs in the United Kingdom: GPAs as
part of initial medical management (Strategy 1); GPAs in
patients with planned PCI, where GPAs are started once
a decision to undertake PCI has been made (Strategy 2);
GPAs as an adjunct to PCI, where the agent is used at the
time of PCI or is started up to 1 hour before the procedure
(Strategy 3); and no use of GPA (usual care; Strategy 4).
Probabilistic sensitivity analysis was used to evaluate
the impact of parameter uncertainty on the adoption deci-
sion. In addition, several scenario analyses were undertaken
to evaluate uncertainty associated with several structural and
data assumptions. These included variations in the sources of
data used to populate the model (e.g., alternative relative risk
estimates, non-UK sources for baseline risk), the inclusion
of an additional strategy to reflect a potentially relevant com-
parator to the GPAs and a risk-based subgroup analysis. Full
details of the results of the sensitivity and scenario analyses
are published elsewhere (41). For this study, we focus on two
of these analyses for the purpose of illustration. We examine,
first, the effect on EVPI of evaluating an additional manage-
ment strategy—clopidogrel, which has been shown to be an
effective treatment for these groups of patients (14), in addi-
tion to the three GPA-based strategies. Second, we perform
a subgroup analysis and evaluate the impact of treating pa-
tients with GPAs who are defined, a priori, as being at either
high- or low-risk of future cardiac events. Data for each of
the sensitivity analyses were taken from published sources
(2;4;14;23).
VOI analysis was undertaken for the base-case model
and for the two sensitivity analyses described above. In each
case, the EVPI was estimated for the full model and for
groups of parameters within it (EVPPI). The parameters were
grouped according to the specific type of study that would
be required to obtain further data on them. A range of sce-
narios is presented to reflect different assumptions related
to the period of time over which the information would be
beneficial (between 5 and 15 years) and for different thresh-
old values for the ICER (between £10,000 and £50,000 per
QALY). Population level EVPI values were estimated using
an estimated annual incidence of 59,756 (32) and a 6% rate
of discount (16).
RESEARCH RECOMMENDATIONS FOR
THE USE OF GPAS FOR PATIENTS WITH
NON-ST ELEVATION ACS
Adoption Decision
The cost-effectiveness of the alternative strategies is com-
pared using standard decision rules (27). Table 1 details the
expected cost and QALYs and ICERs for the base-case model
Table 1. Expected Costs and QALYs for Each Strategy under
Alternative Scenarios
Strategy Expected cost Expected QALYs ICER
Base case model
1 £12,688 7.7875 £5,736a
2 £12,207 7.6839 D
3 £12,188 7.6910 ED
4 £12,119 7.6883
Scenario 1: clopidogrel as a fifth strategy
1 £12,790 7.7630 £5,769a
5 £12,594 7.7173 ED
2 £12,307 7.6591 D
3 £12,287 7.6662 ED
4 £12,216 7.6635
Scenario 2: subgroup analysis by risk
High-risk group
1 £12,450 7.5630 £3,890a
2 £12,884 7.3917 D
3 £11,860 7.3994 ED
4 £11,802 7.3964
Low-risk group
1 £12,967 7.9618 D
2 £12,657 7.9978 D
3 £12,631 7.9980 £800,000b
4 £12,551 7.9979
aICER Strategy 1 versus Strategy 4.
bICER Strategy 3 versus Strategy 4.
QALYs, quality-adjusted life years; D, dominated; ED, extended dominance;
ICER, incremental cost-effectiveness ratio.
and for the two scenarios modeled under sensitivity analy-
ses. For the base-case analysis and clopidogrel sensitivity
analysis, Strategy 2 is not cost-effective because it is more
costly and less effective than Strategy 3 (i.e., dominated) and
Strategy 3 is not cost-effective because of extended domi-
nance (28). Moreover, in the clopidogrel sensitivity analysis,
clopidogrel is also not cost-effective due to extended domi-
nance. Therefore, under both of these scenarios, Strategy 1
(GPAs used as part of medical management) results in an
ICER of around £5,700 per additional QALY in comparison
with standard care (no GPA).
The results differ in the scenario analysis involving risk
subgroups. Here, Strategy 1 remains cost-effective for those
defined as high risk (Strategy 2 and 3 are dominated), with an
ICER of £3,890 when compared with Strategy 4. However,
for the low-risk group, Strategy 1 is dominated and the ICER
of Strategy 3 (GPA in conjunction with PCI) compared with
Strategy 4 is £800,000, which suggests that Strategy 4 (no use
of GPAs) is likely to be considered the most cost-effective
form of management.
VOI Analysis
Population EVPI. For the base-case model, the popu-
lation EVPI ranges from £11.46 million (over 5 years assum-
ing a threshold value of cost-effectiveness of £30K) to £35.56
million (15 years, threshold = £50K) depending on assump-
tions regarding the lifespan of the technology and the value
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Figure 1. Population expected value of perfect information (EVPI) for the base-case and sensitivity analyses models.
of the threshold. If the lifespan of the technology is 10 years
and the threshold for cost-effectiveness is £30,000, the EVPI
is £20.032 million (EVPI per episode at this threshold is £43;
Table 2). In both sensitivity analyses, the EVPI values change
considerably. Figure 1 presents the population EVPI values
under base case assumptions and for the two sensitivity anal-
yses assuming a 10-year lifespan for the technologies. For
the base case, clopidogrel and high-risk subgroup analyses,
EVPI increases up to a local maximum at the point where
the threshold value (λ) is equal to the value of the ICER
for the adoption decision of Strategy 1 relative to Strategy
4 (e.g., £5,738 per additional QALY for the base case). Up
to this value, EVPI is increasing. This is because the uncer-
tainty surrounding the adoption decision is increasing (error
probability increasing), as is the value applied to the con-
sequences of making an incorrect decision (i.e., λ). After
this point, the uncertainty in the adoption decision decreases.
Whereas uncertainty surrounding the adoption decision be-
yond this point begins to fall, the consequences associated
with making an incorrect decision continue to rise. The over-
all effect on the EVPI depends on the interaction between
these terms. For the base-case model, as the threshold value
approaches £18,000 the EVPI falls, implying that the prob-
ability of an incorrect decision is reducing at a rate that is
sufficient to offset the increasing costs of making an incorrect
decision. After this point, the EVPI increases as the threshold
increases, demonstrating that, although the error probability
is still falling, this change is now being outweighed by the
costs of making an incorrect decision.
The pattern of EVPI is different for the low-risk sub-
group analysis. Under this scenario, population EVPI values
are negligible at ceiling ratios below £6,000; at these low
threshold values, the level of decision uncertainty and the
consequences of that uncertainty are both low. After this
point, EVPI continues to increase. This finding is because,
although there is a small probability that each of Strategies
1–3 are cost-effective, this probability increases at higher val-
ues of λ (i.e., there is nonnegligible error probability), and
the consequences of the decision uncertainty are increasing.
Population EVPPI. Table 2 details the population
EVPPI values for groups of parameters, under an assumed
lifespan for the technologies of 10 years. Under base-case
assumptions, it is clear that all of the uncertainty is encapsu-
lated within the relative risks associated with Strategy 1. This
finding suggests that further research would be most bene-
ficial if it were directed toward obtaining better estimates
of the relative treatment effects of GPAs used as medical
management. A similar pattern is observed in the high-risk
sensitivity analysis. When clopidogrel is added as a further
management strategy, there are positive and similar EVPI
values for both the relative risks associated with Strategy
1 and the relative effects of clopidogrel. Further investiga-
tion of the individual parameters making up each relative
risk group identified that, in each case, the relative risk of
death in patients not undergoing an acute PCI accounts for
all decision uncertainty.
The low-risk sensitivity analysis yields interesting re-
sults as it is in this group that the adoption decision changes
from the base-case analysis. Although, with current infor-
mation, the optimum decision is to continue with usual care
(Strategy 4), the VOI analysis suggests that, for a threshold
value of £10,000 per additional QALY, there is value in ob-
taining further information on baseline risk and long-term
outcomes, in addition to further information regarding the
relative benefits of GPAs used as medical management.
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Research Recommendations
The EVPI for the base-case model indicates there may be
considerable value in commissioning further research to re-
duce the uncertainty associated with the adoption decision.
Using base-case assumptions, EVPI is between £47.71 and
£57.81 per patient for threshold values between £10,000 and
£50,000. Translating this finding to a population figure, the
EVPI is between £20 million and £26.9 million, assuming
the lifespan of the technology is 10 years. This value repre-
sents an upper limit on the costs associated with the decision
uncertainty; thus, any costs associated with any proposed fur-
ther research should not exceed this amount if this research
is to be considered efficient.
EVPI is driven exclusively by the relative risk of death
in patients not undergoing an initial PCI in Strategy 1. This
would suggest that future research should be directed toward
reducing the uncertainty associated with the relative risk of
death in ACS patients who are prescribed GPAs and who
do not undergo a PCI procedure in the acute phase. This is
not entirely surprising because, at the time of the analysis,
approximately 95% of patients did not receive a PCI during
their initial episode.
When clopidogrel is included as a treatment option,
Strategy 1 remains the optimal decision but EVPI increases.
This finding is because there are only small differences in cost
and outcome between the clopidogrel option and Strategy 1.
Although Strategy 1 remains the optimal adoption decision,
the inclusion of clopidogrel results in a significant increase
in the level of uncertainty surrounding the adoption decision
itself, because there is a .33 probability that clopidogrel is
cost-effective. This additional uncertainty surrounding the
adoption decision explains the high EVPI. The results of this
scenario suggest that further research to identify the relative
benefits of clopidogrel and GPAs as part of medical man-
agement, and compared with the current service provisions,
would be of benefit.
When the model is run for separate subgroups, we see
a change in the adoption decision depending on risk. For
high-risk patients, the optimal decision remains Strategy 1
and the pattern of EVPI results mirror the base case model,
although the magnitude of the values per patient increase. For
low-risk patients, although the adoption decision changes,
the decision uncertainty remains. It is clear that, for low-
risk patients, there is value in obtaining further information
regarding both their baseline risks of death and nonfatal MI
and the relative effects of treatment.
DISCUSSION
As the demand for health care increases in developed coun-
tries, so too does expenditure on research and development
on new technologies to satisfy this demand. After 25 years
of active research into the methods and application of cost-
effectiveness in health care, it is now widely accepted that
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these methods should be used to inform decisions about
which technologies should be reimbursed within collectively
funded systems. Given the volume of resources at stake, the
complexities and uncertainties involved and the inevitable
need to set priorities, it is now essential to use similar an-
alytic frameworks to identify the most cost-effective areas
for research. Value of information analysis provides a set of
methods for research prioritization, which are consistent with
the methods of cost-effectiveness analysis for technologies
and which have a firm theoretical underpinning in statistical
decision theory (36;38;39).
An important feature of value of information analysis
is that the potential value of additional research is assessed
assuming that clinicians will undertake practice that research
indicates is the most cost-effective. In other words, there
is no assumed gap between practice identified as optimal
and actual practice. The rationale for this assumption is that
the issues of what is appropriate (i.e., cost-effective) clinical
practice and how such practice is implemented are quite sep-
arable. Value of information methods are focused on the po-
tential value of additional information in reducing decision
uncertainty; implementation is concerned with the polices
used to get practitioners to undertake practice that research
identifies as optimal. Research currently is under way to
develop methods that formally consider the value of addi-
tional information through research and the potential value
of implementation interventions within the same analytical
framework (18;19).
The glycoprotein model used in the case study was de-
veloped to inform the NICE appraisal of those therapies. In
September 2002, NICE issued guidance that, among other
things, GPAs should be considered as part of medical man-
agement for patients with unstable angina or non-ST segment
elevation MI (33). The guidance notes recognized that there
was considerable uncertainty associated with the evidence
base in this area and made some recommendations for fur-
ther research. These recommendations included research to
evaluate the effects of GPAs in current UK practice in non-ST
segment elevation ACS patients who are not scheduled for
PCI, and the efficacy of GPAs in subgroups such as women.
There were also recommendations for research to establish
the relative roles of GPAs and clopidogrel in the short-term
management of ACS patients and into clinical risk factors
that could be used in treatment allocation.
These research recommendations, as for all other NICE
technology appraisals, were not based on formal VOI analy-
sis (the VOI analysis in the case study was undertaken after
the appraisal was completed). Rather, they are based on the
Appraisal Committee’s understanding of the major gaps in
the evidence. Comparing NICE’s research recommendations
with those suggested by the VOI analysis presented here in-
dicates that they are broadly consistent. However, the VOI
analysis overall and for groups of parameters has the po-
tential to inform much more detailed recommendations. For
example, the case study suggests that the key area of un-
certainty relates to the relative effectiveness of GPA versus
standard medical management, and also in comparison with
clopidogrel.
Two general issues are highlighted by this analysis.
These issues relate to the impact of scope and patient het-
erogeneity. Whereas the impact of broadening the scope of
the analysis for the case study presented here did not change
the initial adoption decision, it had marked impact on the po-
tential value of future research. Moreover, taking account of
the heterogeneity between patient groups in this case study
showed clearly how both the adoption decision and the type
of future research required can differ between groups. If the
VOI approach is going to be used in research prioritization
then it is essential that the scope of the analysis is suffi-
ciently broad to encompass all relevant treatment alterna-
tives and that the impact of heterogeneity is reflected in both
the adoption decision and the decision to conduct further
research.
It is important to emphasize that the EVPI represents a
maximum value of additional research. As such, it represents
a necessary, rather than a sufficient, condition for future re-
search. As long as the cost of a given research project is less
than the EVPI, there is at least a potential for it to repre-
sent an efficient use of resources. To establish a sufficient
condition and decide if further research will be worthwhile
and identify efficient research design, we need to consider
the marginal benefits and marginal cost of sample informa-
tion. The same framework of value of information analysis
can be extended to establish the expected value of sample
information for particular research designs and to compare
these expected benefits of research to the expected costs (1).
This type of analysis provides a societal payoff to alternative
designs and can be used to establish optimal sample size,
optimal allocation of patients within a clinical trial, appro-
priate follow-up, and which end points should be included in
the design. Indeed this framework can be used to identify a
portfolio of different types of studies that may be required to
provide evidence sufficient to support the use of a healthcare
technology (9;13).
POLICY IMPLICATIONS
This study has presented the application of value of informa-
tion methods to a policy relevant decision problem recently
faced by the UK’s NICE. What is the policy relevance of this
work? The characteristics of the GPA decision problem are
consistent with most of those faced by health systems inter-
nationally: limited efficacy (as opposed to effectiveness) data
from short-term trials largely undertaken to license pharma-
ceuticals provide a highly uncertain basis to determine the
cost-effectiveness of the product and, hence, its appropriate-
ness for funding/reimbursement. The use of decision model-
ing and value of information analysis allows health systems
to establish (i) whether a technology is cost-effective, given
existing (often limited) evidence; and (ii) the type and extent
INTL. J. OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 22:3, 2006 385
Philips et al.
of additional evidence that needs to be gathered to support
potential revisions of the decision in the future. As such, the
methods provide a coherent framework within which to ad-
dress the question—When do we have sufficient evidence to
support the use of a new technology?
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